

# Bernd Kasper

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1641432/publications.pdf>

Version: 2024-02-01

103  
papers

2,686  
citations

236925

25  
h-index

223800

46  
g-index

105  
all docs

105  
docs citations

105  
times ranked

2914  
citing authors

#	ARTICLE	IF	CITATIONS
1	Financial toxicity in sarcoma patients and survivors in Germany: results from the multicenter PROSa study. <i>Supportive Care in Cancer</i> , 2022, 30, 187-196.	2.2	10
2	The association of Health-Related Quality of Life and 1-year-survival in sarcoma patients—results of a Nationwide Observational Study (PROSa). <i>British Journal of Cancer</i> , 2022, 126, 1346-1354.	6.4	6
3	Global Patient Involvement in Sarcoma Care—A Collaborative Initiative of the Connective Tissue Oncology Society (CTOS) & Sarcoma Patients EuroNet (SPAEN). <i>Cancers</i> , 2022, 14, 854.	3.7	2
4	What Clinical Trials Are Needed for Treatment of Leiomyosarcoma?. <i>Current Treatment Options in Oncology</i> , 2022, 23, 439-449.	3.0	5
5	Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Exploratory, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database. <i>Sarcoma</i> , 2022, 2022, 1-13.	1.3	1
6	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	1.6	15
7	Sounding the Alarm on Leiomyosarcoma Recurrence: Role of Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2022, , .	7.0	0
8	Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 “CaboGIST”™. <i>Acta Oncologica</i> , 2022, 61, 663-668.	1.8	1
9	Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the EORTC 62092/22092 STRASS trial. <i>Cancer</i> , 2022, 128, 2796-2805.	4.1	14
10	First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. <i>Cancer</i> , 2022, 128, 2932-2938.	4.1	3
11	Management of Desmoid Tumors. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 447-458.	1.5	2
12	Transferability of Health-Related Quality of Life Data of Large Observational Studies to Clinical Practice: Comparing Retroperitoneal Sarcoma Patients from the PROSa Study to a TARPS-WG Cohort. <i>Oncology Research and Treatment</i> , 2022, 45, 660-669.	1.2	2
13	The challenge of drug approval in rare cancers. <i>Cancer</i> , 2021, 127, 837-839.	4.1	5
14	Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa Study. <i>Oncology Research and Treatment</i> , 2021, 44, 301-312.	1.2	13
15	The Landmark Series: Desmoid. <i>Annals of Surgical Oncology</i> , 2021, 28, 1682-1689.	1.5	10
16	Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National Leiomyosarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). <i>Cancers</i> , 2021, 13, 886.	3.7	17
17	Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma. <i>JAMA Oncology</i> , 2021, 7, 255.	7.1	17
18	Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 T <i>Cancers</i> , 2021, 13, 1223.	3.7	15

#	ARTICLE	IF	CITATIONS
19	Gene Expression in Solitary Fibrous Tumors (SFTs) Correlates with Anatomic Localization and NAB2-STAT6 Gene Fusion Variants. <i>American Journal of Pathology</i> , 2021, 191, 602-617.	3.8	30
20	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	4.1	96
21	Desmoid-type fibromatosis: toward a holistic management. <i>Current Opinion in Oncology</i> , 2021, 33, 309-314.	2.4	5
22	Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Preliminary results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc) for the non-L sarcoma cohort. <i>Journal of Clinical Oncology</i> , 2021, 39, 11545-11545.	1.6	4
23	Molecular and Pathological Profiling of Corresponding Treatment-Naïve and Neoadjuvant Pazopanib-Treated High-Risk Soft Tissue Sarcoma Samples of the GISG-04/NOPASS Study. <i>Biology</i> , 2021, 10, 639.	2.8	1
24	Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa). <i>European Journal of Cancer Care</i> , 2021, 30, e13484.	1.5	7
25	Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas. <i>European Journal of Cancer</i> , 2021, 154, 253-268.	2.8	8
26	Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. <i>European Journal of Cancer</i> , 2021, 156, 12-23.	2.8	26
27	Incorporating the Patient Voice in Sarcoma Research: How Can We Assess Health-Related Quality of Life in This Heterogeneous Group of Patients? A Study Protocol. <i>Cancers</i> , 2021, 13, 1.	3.7	189
28	SI-Guideline Cutaneous Angiosarcomas – Update 2021. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1801-1812.	0.8	2
29	Health-Related Quality of Life Issues Experienced by Thoracic and Breast Sarcoma Patients: A Rare and Understudied Group. <i>Journal of Clinical Medicine</i> , 2021, 10, 5334.	2.4	2
30	EJSO educational Special issue from the TARPSWG - Standard medical treatment and new options in retroperitoneal sarcoma. <i>European Journal of Surgical Oncology</i> , 2021, , .	1.0	3
31	PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas – A Preclinical and Translational Study. <i>Cancers</i> , 2021, 13, 6295.	3.7	0
32	EORTC SPECTRA – AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe. <i>International Journal of Cancer</i> , 2020, 147, 1180-1184.	5.1	11
33	Desmoid tumors: To treat or not to treat, That is the question. <i>Cancer</i> , 2020, 126, 5213-5221.	4.1	43
34	The challenge of treating elderly patients with advanced bone and soft tissue sarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 155, 103108.	4.4	8
35	Unravelling the heterogeneity of soft tissue and bone sarcoma patients – health-related quality of life: a systematic literature review with focus on tumour location. <i>ESMO Open</i> , 2020, 5, e000914.	4.5	19
36	Prognosis of Patients with Metastatic Soft Tissue Sarcoma: Advances in Recent Years. <i>Oncology Research and Treatment</i> , 2020, 43, 613-619.	1.2	32

#	ARTICLE	IF	CITATIONS
37	Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: a multicentre, cluster-randomised trial within the German Interdisciplinary Sarcoma Group (GISG). <i>BMJ Open</i> , 2020, 10, e035546.	1.9	6
38	Career and Financial Situation of Patients Diagnosed with Soft Tissue Sarcomas. <i>Oncology Research and Treatment</i> , 2020, 43, 539-548.	1.2	4
39	Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 3555-3564.	1.6	56
40	Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 957-963.	2.4	8
41	The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany – Cross-Sectional Results of a Nationwide Observational Study (PROSa). <i>Cancers</i> , 2020, 12, 3590.	3.7	31
42	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020, 126, 2637-2647.	4.1	86
43	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 96-107.	2.8	243
44	The EORTC QLQ-C30 Summary Score as a Prognostic Factor for Survival of Patients with Cancer: A Commentary. <i>Oncologist</i> , 2020, 25, e610-e611.	3.7	16
45	Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors. <i>Molecular and Clinical Oncology</i> , 2020, 13, 1-1.	1.0	7
46	We couldn't resist comparing central with local RECIST1.1 and with Choi assessment: Exploratory analysis of tumor imaging in EORTC STBSG Phase 2 trial 1317 – CaboGIST. <i>Journal of Clinical Oncology</i> , 2020, 38, e23563-e23563.	1.6	0
47	Current State of Sarcoma Care in Germany: Results of an Online Survey of Physicians. <i>Oncology Research and Treatment</i> , 2019, 42, 589-598.	1.2	5
48	The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. <i>European Journal of Cancer</i> , 2019, 109, 51-60.	2.8	134
49	Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic 18F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group. <i>Cancers</i> , 2019, 11, 790.	3.7	11
50	The challenge of finding new therapeutic avenues in soft tissue sarcomas. <i>Clinical Sarcoma Research</i> , 2019, 9, 5.	2.3	8
51	Preoperative Pazopanib in High-Risk Soft Tissue Sarcoma: Phase II Window-of Opportunity Study of the German Interdisciplinary Sarcoma Group (NOPASS/GISG-04). <i>Annals of Surgical Oncology</i> , 2019, 26, 1332-1339.	1.5	12
52	Desmoid tumor: A focus set on a challenging but understudied rare disease. <i>Cancer</i> , 2019, 125, 2532-2533.	4.1	2
53	The Value of Anti-angiogenics in Soft Tissue Sarcoma Therapy. , 2019, , 465-473.		0
54	Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC – STBSG). <i>International Journal of Cancer</i> , 2018, 142, 2610-2620.	5.1	32

#	ARTICLE	IF	CITATIONS
55	Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nature Communications, 2018, 9, 144.	12.8	197
56	Strengthening health data on a rare and heterogeneous disease: sarcoma incidence and histological subtypes in Germany. BMC Public Health, 2018, 18, 235.	2.9	64
57	Working to improve the management of sarcoma patients across Europe: a policy checklist. BMC Cancer, 2018, 18, 424.	2.6	18
58	Clinical Presentation of Gastrointestinal Stromal Tumors. Visceral Medicine, 2018, 34, 335-340.	1.3	42
59	Health Care Resource Utilization and Costs among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France. Sarcoma, 2018, 2018, 1-13.	1.3	3
60	Treatment Patterns and Survival among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France. Sarcoma, 2018, 2018, 1-12.	1.3	27
61	Randomized comparison of pazopanib (PAZ) and doxorubicin (DOX) in the first line treatment of metastatic soft tissue sarcoma (STS) in elderly patients (pts): Results of a phase II study (EPAZ).. Journal of Clinical Oncology, 2018, 36, 11506-11506.	1.6	11
62	Treatment of angiosarcoma with pazopanib and paclitaxel: Results of the phase II trial of the German Interdisciplinary Sarcoma Group (GISG-06 EVA) study.. Journal of Clinical Oncology, 2018, 36, 11570-11570.	1.6	2
63	Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).. Journal of Clinical Oncology, 2018, 36, 11574-11574.	1.6	6
64	Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE.. Journal of Clinical Oncology, 2018, 36, 11540-11540.	1.6	1
65	Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). European Journal of Cancer, 2017, 76, 60-67.	2.8	88
66	Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients. Cancer Chemotherapy and Pharmacology, 2017, 80, 433-439.	2.3	7
67	The Value of Anti-Angiogenics in Soft Tissue Sarcoma Therapy. , 2017, , 1-10.		0
68	Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS). BMJ Open, 2016, 6, e009558.	1.9	9
69	Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03). Radiation Oncology, 2016, 11, 77.	2.7	22
70	Vorinostat in refractory soft tissue sarcomas â€“ Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO). European Journal of Cancer, 2016, 64, 74-82.	2.8	28
71	Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01). Annals of Surgical Oncology, 2016, 23, 1924-1927.	1.5	58
72	Phase II clinical trial evaluating the activity and tolerability of pazopanib in patients (pts) with advanced and/or metastatic liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) Studyâ€”NCT01692496.. Journal of Clinical Oncology, 2016, 34, 11039-11039.	1.6	11

#	ARTICLE	IF	CITATIONS
73	Primary and secondary angiosarcomas: a comparative single-center analysis. <i>Clinical Sarcoma Research</i> , 2015, 5, 14.	2.3	16
74	Combination of Trabectedin and Gemcitabine for Advanced Soft Tissue Sarcomas: Results of a Phase I Dose Escalating Trial of the German Interdisciplinary Sarcoma Group (GISG). <i>Marine Drugs</i> , 2015, 13, 379-388.	4.6	9
75	Systemic Treatment Approaches for Sporadic Desmoid-Type Fibromatosis: Scarce Evidence and Recommendations. <i>Oncology Research and Treatment</i> , 2015, 38, 244-248.	1.2	24
76	EPAZ: A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma of the Working Group Medical Oncology (AIO) and German Interdisciplinary Sarcoma Group (GISG).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS10576-TPS10576.	1.6	0
77	Adult Pleomorphic Rhabdomyosarcoma: A Multicentre Retrospective Study. <i>Anticancer Research</i> , 2015, 35, 6213-7.	1.1	21
78	Metastatic pattern of late metastases of gastrointestinal stromal tumors and the contribution radiation therapy for disease control.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10554-10554.	1.6	0
79	Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: A study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931. <i>European Journal of Cancer</i> , 2013, 49, 449-456.	2.8	37
80	Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib. <i>BioMed Research International</i> , 2013, 2013, 1-7.	1.9	21
81	Dynamic PET With FDG in Patients With Unresectable Aggressive Fibromatosis. <i>Clinical Nuclear Medicine</i> , 2012, 37, 943-948.	1.3	11
82	Desmoid Tumors: Clinical Features and Treatment Options for Advanced Disease. <i>Oncologist</i> , 2011, 16, 682-693.	3.7	224
83	Pazopanib: a promising new agent in the treatment of soft tissue sarcomas. <i>Future Oncology</i> , 2011, 7, 1373-1383.	2.4	34
84	Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1481-1489.	6.4	28
85	Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1876-1882.	6.4	46
86	Impact of Dynamic <sup>18</sup> F-FDG PET on the Early Prediction of Therapy Outcome in Patients with High-Risk Soft-Tissue Sarcomas After Neoadjuvant Chemotherapy: A Feasibility Study. <i>Journal of Nuclear Medicine</i> , 2010, 51, 551-558.	5.0	49
87	The use of fluorine-18 fluorodesoxyglycose-positron emission tomography for treatment monitoring in patients with soft tissue sarcomas. <i>Hellenic Journal of Nuclear Medicine</i> , 2010, 13, 40-4.	0.3	5
88	The Use of Positron Emission Tomography in Soft Tissue Sarcoma Patients under Therapy with Trabectedin. <i>Marine Drugs</i> , 2009, 7, 331-340.	4.6	10
89	New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1159-1167.	2.4	16
90	Early Prediction of Therapy Outcome in Patients with High-Risk Soft Tissue Sarcoma Using Positron Emission Tomography. <i>Onkologie</i> , 2008, 31, 107-112.	0.8	21

#	ARTICLE	IF	CITATIONS
91	Large Institutional Experience with Dose-Intensive Chemotherapy and Stem Cell Support in the Management of Sarcoma Patients. <i>Oncology</i> , 2007, 73, 58-64.	1.9	12
92	Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge?. <i>Current Opinion in Oncology</i> , 2007, 19, 336-340.	2.4	17
93	Standards and Novel Therapeutic Options in the Treatment of Patients with Soft Tissue Sarcoma. <i>Reviews on Recent Clinical Trials</i> , 2007, 2, 206-211.	0.8	14
94	Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. <i>Leukemia and Lymphoma</i> , 2007, 48, 746-753.	1.3	48
95	Novel treatment strategies for malignant melanoma: A new beginning?. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 62, 16-22.	4.4	30
96	Novel treatment strategies for soft tissue sarcoma. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 62, 9-15.	4.4	29
97	Dose-Intensive Chemotherapy with Stem Cell Support as a Treatment Strategy for Bone and Soft-Tissue Sarcomas. <i>Current Stem Cell Research and Therapy</i> , 2006, 1, 29-35.	1.3	3
98	Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp. <i>Anti-Cancer Drugs</i> , 2006, 17, 1223-1225.	1.4	21
99	Multimodality Treatment in Adult Patients with High-risk Soft-tissue Sarcomas. <i>Chinese-German Journal of Clinical Oncology</i> , 2006, 5, 2-7.	0.1	1
100	Treatment of Gastrointestinal Stromal Tumor with Imatinib Mesylate: A Retrospective Single-Center Experience in Heidelberg. <i>Digestive Diseases</i> , 2006, 24, 207-211.	1.9	6
101	A new therapeutic approach in patients with advanced sarcoma. <i>International Journal of Clinical Oncology</i> , 2005, 10, 438-440.	2.2	10
102	Is There an Indication for High-Dose Chemotherapy in the Treatment of Bone and Soft-Tissue Sarcoma?. <i>Oncology</i> , 2005, 68, 115-121.	1.9	25
103	Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?. <i>Supportive Care in Cancer</i> , 2004, 12, 205-207.	2.2	19